Skip to content
Screener

Financing Cash Flow at other companies

AbbVie logo
AbbVieABBV
$919M+173%
Bausch + Lomb logo
Bausch + LombBLCO
$34M-62.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%
HRO
HarrowHROW
$48.91M+212,561%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$19.99M+8,300%
Schering-Plough logo
Schering-PloughSGP
$157.76M+215%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from issuance of common stock, net of paid issuance costs134,771
Proceeds from sale of common stock under employee stock purchase plan1,4381,101
Proceeds from exercise of stock options3,0682,642
Net cash provided by financing activities4,506138,514
Net increase in cash, cash equivalents and restricted cash20,3931,830
Cash, cash equivalents and restricted cash at beginning of period186,20397,381
Cash, cash equivalents and restricted cash at end of period$206,596$99,211
Supplemental Disclosures From Noncash, Investing and Financing Activities:

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s financing cash flow?
Tarsus Pharmaceuticals, Inc. (TARS) reported financing cash flow of $3.3M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s financing cash flow increased by 69.2% year-over-year, from $1.95M to $3.3M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s financing cash flow?
Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s financing cash flow has grown at a 15.1% compound annual growth rate (CAGR), from $94.12M to $143.39M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude